Archive for the ‘ori investigations’ Category
The stories behind several recent inscrutable retraction notices became a bit more clear today when the Office of Research Integrity (ORI) issued findings in cases involving former researchers at the University of Chicago and the University of California, San Francisco.
The Office of Research Integrity (ORI) has sanctioned Kaushik Deb, a former post-doc at the University of Missouri-Columbia, who “engaged in misconduct in science by intentionally, knowingly, and recklessly” fabricating data in papers in both Science and Nature (which ultimately rejected his manuscript).
Deb was big news in 2007, when Science retracted his paper. Articles about the case appeared in many outlets, including The Scientist and USA Today. At the time, Missouri’s research integrity officer, Rob Hall, told the Columbia Tribune that: Read the rest of this entry »
A former Vanderbilt University biomedical engineer committed fraud on a massive scale, according to a new Office of Research Integrity (ORI) report.
Igor Dzhura is banned from receiving federal funding for three years, and is retracting six papers, which have been cited more than 500 times. Since leaving Vanderbilt, he has worked at SUNY Upstate Medical University, and now works at Novartis.
According to the ORI, Dzhura was a busy boy at Vanderbilt, faking images and drastically inflating the number of experiments he conducted by duplicating computer files and saving them in nested folders. The total body count from his work includes: Read the rest of this entry »
A paper by a former postdoc at MD Anderson Cancer Center who “admitted to knowingly and intentionally falsifying” a figure has been retracted.
In August, the Office of Research Integrity announced that it had sanctioned Jun Fu for faking data in a study of the results of a mouse study of NVP-HSP990, a Novartis compound designed to fight brain tumors. Here’s the notice for the study in question, published in Cancer Research:
Read the rest of this entry »
The former director of the X-ray crystallography lab at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, faked findings in three papers, according to the Office of Research Integrity.
Two of the three papers by Bijan Ahvazi were published in 2004, and later retracted in 2007, while the other was rejected: Read the rest of this entry »
The Office of Research Integrity (ORI) has ruled in a case we’ve been following for nearly two years — and which seems to have been launched after Retraction Watch readers took a careful look at figures from what appeared to be an unrelated case.
Takao Takahashi and Makato Suzuki, both former postdocs at a cancer research center at UT-Southwestern, both “knowingly, intentionally, and recklessly falsified data” in a total of 10 papers, according to the ORI. Takahashi, now at Gifu University in Japan, was responsible for fakery in four papers, while Suzuki, now at Kumamoto University Hospital, also in Japan, falsified data in six.
We reported on the retraction of the four Takahashi papers, and one of the Suzuki papers, in November 2012. At that time, Adi Gazdar, the head of the lab where the researchers worked, told us that
Read the rest of this entry »
Nasser Chegini, an ob-gyn formerly on the faculty at the University of Florida who has been the subject of an Office of Research Integrity (ORI) inquiry for several years, has a second retraction.
Chegini is suspected of having used bogus data in some of his work — research backed in part by some $4 million in federal funding.
That’s an important question, with an answer that may help determine how much attention some people pay to research misconduct. But it’s one that hasn’t been rigorously addressed.
Seeking some clarity, Andrew Stern, Arturo Casadevall, Grant Steen, and Ferric Fang looked at cases in which the Office of Research Integrity had determined there was misconduct in particular papers. In their study, published today in eLife: Read the rest of this entry »
A former postdoc at MD Anderson Cancer Center faked the results of a mouse study of a Novartis compound designed to fight brain tumors, according to the Office of Research Integrity (ORI).
Jun Fu “admitted to knowingly and intentionally falsifying Figure 8a” in “Novel HSP90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumor–Initiating Cells,” a paper published in Cancer Research on May 15, 2013:
The Office of Research Integrity has sanctioned a former researcher in the lab of Linda Buck, winner of the 2004 Nobel Prize in Physiology or Medicine, for falsifying data in two papers written with the support of grants from the National Institutes of Health.
The researcher, Zou Zhihua, worked with Buck as a post-doc at Harvard and then at the Fred Hutchinson Cancer Research Center, in Seattle, Buck’s current home. After leaving there in 2005, he spent three years at the University of Texas Medical Branch in Galveston, and now appears to be a faculty member at Jilin University in China.
According to the report: